Trandolapril

• Description:

  Trandolapril (RU44570) is a nonsulfhydryl proagent that is hydrolysed to the active diacid Trandolaprilat. Trandolapril is an orally administered angiotensin converting enzyme (ACE) inhibitor that has been used in the treatment of hypertension and congestive heart failure (CHF), and after myocardial infarction (MI) [1].

• Product Name Alternative:

  RU44570

• UNSPSC:

  12352005

• Hazard Statement:

  H360

• Target:

  Angiotensin-converting Enzyme (ACE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  COVID-19-anti-virus

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/trandolapril.html

• Purity:

  99.98

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C([C@H]1N(C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)C)=O)[C@@]3([H])CCCC[C@]3([H])C1)O

• Molecular Formula:

  C24H34N2O5

• Molecular Weight:

  430.54

• Precautions:

  H360

• References & Citations:

  [1]Peters DC, et al. Trandolapril. An update of its pharmacology and therapeutic use in cardiovascular disorders. Drugs. 1998 Nov;56 (5) :871-93.|[2]Tan X, et al. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009 Dec;76 (12) :1248-57.|[3]Koffi I, et al. Prevention of arterial structural alterations with verapamil and trandolapril and consequences for mechanical properties in spontaneously hypertensive rats. Eur J Pharmacol. 1998 Nov 13;361 (1) :51-60.|[4]Chobanian AV, et al. Trandolapril inhibits atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Hypertension. 1992 Oct;20 (4) :473-7.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [87679-37-6]